经过26周的治疗，联合用药的病人中有57%获得缓解，与之相比，在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
这些病人中，通过联合治疗的有69%的人获得缓解而在英夫利昔单抗组中为57%，硫唑嘌呤组中只有28%的到缓解。
Among these patients, 69% achieved remission with the combination treatment compared to 57% of those on Remicade alone and to 28% of those on azathioprine alone.
背景在克罗恩病患者中，英夫利西单抗和硫唑嘌呤单药治疗或联合治疗的相对疗效和安全性尚未被了解。
Background the comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
背景在克罗恩病患者中，英夫利西单抗和硫唑嘌呤单药治疗或联合治疗的相对疗效和安全性尚未被了解。
Background the comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
应用推荐